No lab visits. No venipuncture. No phlebotomist. QDX Bio replaces fragmented laboratory testing with a single digital platform that delivers comprehensive results—faster, cheaper, and from the comfort of home.
Modern diagnostic testing is fragmented, expensive, and inefficient. Patients and clinicians rely on dozens of separate assays, multiple blood draws, long turnaround times, and incomplete datasets to understand health status. This limits preventative care, slows clinical decision-making, and drives unnecessary cost.
QDX Bio replaces fragmented testing with a unified digital platform capable of delivering an expanding library of biomarkers through a single test at $199, with faster turnaround and richer longitudinal insight. Using proprietary signal processing and clinically validated biomarker modeling, the platform continuously grows its biomarker coverage.
A single drop of blood, collected at home. No venipuncture, no phlebotomist, no lab visit. Results delivered digitally, eliminating the friction of traditional diagnostic workflows.
As new biomarkers are validated, previously collected digital signatures can be re-analyzed—enabling patients and clinicians to access additional insights without repeat testing.
The platform architecture supports continuous expansion of biomarker coverage. From hundreds at launch to 100,000+, each new validation increases the value of every test—past, present, and future.
Licensed for worldwide deployment, enabling international expansion through regional partners and sublicensing arrangements. Capital-light global scale while preserving data and platform control.
Track hundreds of biomarkers over time from a single platform. Clinicians and patients gain a richer, more complete picture of health trajectories with every test.
Per-test revenue, practitioner subscriptions, enterprise partnerships, and international sublicensing. Post-validation, designed for self-sustaining growth funded through operating revenue.
The convergence of advanced signal processing, validated biomarker inference models, and growing consumer demand for accessible, data-driven health testing creates a unique window to build the definitive digital diagnostics platform.
Launch for early revenue through laboratory-developed test pathway.
Independent clinical validation to build evidence base.
Large-scale studies generating revenue and real-world data.
Comprehensive submission supported by extensive clinical evidence.
Complete third-party validation and paid clinical studies.
Grow the biomarker library from hundreds toward thousands.
Launch initial testing through longevity and functional medicine channels.
Scale infrastructure for growing test volume and data processing.
Full technical documentation, validation plans, and commercial details available under mutual NDA.